At the boundary between pharmacognosy and molecular biology,molecular pharmacognosy has developed as a new borderline discipline.This paper reviews the methods,application,and prospect of molecular pharmacognosy.DNA m...At the boundary between pharmacognosy and molecular biology,molecular pharmacognosy has developed as a new borderline discipline.This paper reviews the methods,application,and prospect of molecular pharmacognosy.DNA marker is one of genetic markers and some molecular marker methods which have been successfully used for genetic diversity identification and new medicinal resources development.Recombinant DNA technology provides a powerful tool that enables scientists to engineer DNA sequences.Gene chip technique could be used in determination of gene expression profiles,analyses of polymorphisms,construction of genomic library,analysis of mapping,and sequencing by hybridization.Using the methods and theory of molecular biology and pharmacognosy,molecular pharmacognosy represents an extremely prospective branch of pharmacognosy and focuses on the study of systemic growth of medicinal plants,identification and evaluation of germplasm resources,plant metabolomics and production of active compounds.Furthermore,the great breakthrough of molecular pharmacognosy could be anticipated on DNA fingerprint analysis,cultivar improvement,DNA identification,and a global DNA barcoding system in the future.展开更多
AIM To investigate SBA2 expression in CRC cell lines snd surgical specimens of CRC and sutologous healthy mucosa.METHODS Reverse transcription-polymerase chain reaction (RT-PCR) was used for relative quantification of...AIM To investigate SBA2 expression in CRC cell lines snd surgical specimens of CRC and sutologous healthy mucosa.METHODS Reverse transcription-polymerase chain reaction (RT-PCR) was used for relative quantification of SBA2 mRNA levels in 4 human CRC cell lines with different grades of differentiation and 30 clinical samples.Normalization of the results was achieved by simultaneous amplification of β-actin as an internal control.RESULTS In the exponential range of amplification, fairly good linearity demonstrated identical amplification efficiency for SBA2 and β-actin (82%). Markedly lower levels of SBA2 mRNA were detectable in tumors, as compared with the coupled normal counterparts ( P ＜ 0.01 ). SBA2 expression was significantly (0.01 ＜ P ＜0.05) correlated with the grade of differentiation in CRC,with relatively higher levels in well-differentiated samples and lower in poorly-differentiated cases. Of the 9 cases with lymph nodes affected, 78% (7/9) had reduced SBA2 mRNA expression in contrast to 24% (5/21) in nonmetastasis samples (0.01 ＜ P ＜ 0.05 ).CONCLUSION SBA2 gene might be a promising novel biomarker of cell differentiation in colorectal cancer and its biological features need further studies.展开更多
文摘At the boundary between pharmacognosy and molecular biology,molecular pharmacognosy has developed as a new borderline discipline.This paper reviews the methods,application,and prospect of molecular pharmacognosy.DNA marker is one of genetic markers and some molecular marker methods which have been successfully used for genetic diversity identification and new medicinal resources development.Recombinant DNA technology provides a powerful tool that enables scientists to engineer DNA sequences.Gene chip technique could be used in determination of gene expression profiles,analyses of polymorphisms,construction of genomic library,analysis of mapping,and sequencing by hybridization.Using the methods and theory of molecular biology and pharmacognosy,molecular pharmacognosy represents an extremely prospective branch of pharmacognosy and focuses on the study of systemic growth of medicinal plants,identification and evaluation of germplasm resources,plant metabolomics and production of active compounds.Furthermore,the great breakthrough of molecular pharmacognosy could be anticipated on DNA fingerprint analysis,cultivar improvement,DNA identification,and a global DNA barcoding system in the future.
文摘AIM To investigate SBA2 expression in CRC cell lines snd surgical specimens of CRC and sutologous healthy mucosa.METHODS Reverse transcription-polymerase chain reaction (RT-PCR) was used for relative quantification of SBA2 mRNA levels in 4 human CRC cell lines with different grades of differentiation and 30 clinical samples.Normalization of the results was achieved by simultaneous amplification of β-actin as an internal control.RESULTS In the exponential range of amplification, fairly good linearity demonstrated identical amplification efficiency for SBA2 and β-actin (82%). Markedly lower levels of SBA2 mRNA were detectable in tumors, as compared with the coupled normal counterparts ( P ＜ 0.01 ). SBA2 expression was significantly (0.01 ＜ P ＜0.05) correlated with the grade of differentiation in CRC,with relatively higher levels in well-differentiated samples and lower in poorly-differentiated cases. Of the 9 cases with lymph nodes affected, 78% (7/9) had reduced SBA2 mRNA expression in contrast to 24% (5/21) in nonmetastasis samples (0.01 ＜ P ＜ 0.05 ).CONCLUSION SBA2 gene might be a promising novel biomarker of cell differentiation in colorectal cancer and its biological features need further studies.
